Compugen LTD Form 4 insider transactions

Zurit Levine, SVP, Business Development of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

David Silberman, Chief Financial Officer of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Eran Ophir, President and CEO and a Director of Compugen Ltd, received 200,000 shares of common stock on July 29, 2026.

Anat Cohen-Dayag, a Director of Compugen Ltd, received 100,000 shares of common stock on July 29, 2026.

Eran Perry, a Director of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Pierre Ferre, Chief Operating Officer of Compugen Ltd, received 70,000 shares of common stock on July 29, 2026.

Russo Sharon Kredo, SVP, Research & Discovery of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Mathias Hukkelhoven, a Director of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Gilead Halevy, a Director of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Sanford S Zweifach, a Director of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Michelle Mahler, Chief Medical Officer of Compugen Ltd, reported multiple transactions in common stock on July 29, 2026.

Zurit Levine, SVP, Business Development of Compugen Ltd, sold 1,875 shares of common stock on July 9, 2026 for $2.50 per share.

Zurit Levine, SVP of Business Development at CompuGen Ltd., executed a Rule 10b5-1 plan transaction involving the purchase and sale of ordinary shares.

Ophir Eran, President and CEO of Compugen Ltd., reported the sale of 5,000 ordinary shares for $3.20 per share, executed under a pre-established Rule 10b5-1 trading plan.

Compugen Ltd. CEO Ophir Eran executed a Rule 10b5-1 trading plan, acquiring 5,000 ordinary shares and selling 5,000 ordinary shares.

CompuGen Ltd. SVP of Business Development, Zurit Levine, executed a Rule 10b5-1 plan transaction involving the acquisition and disposition of ordinary shares.

Zurit Levine, SVP of Business Development at CompuGen Ltd., filed an amended Form 4 to correct the earliest transaction date to April 10, 2026, with no changes to other reported transactions.

Zurit Levine, SVP of Business Development at Compugen Ltd., reports transactions involving the acquisition and disposition of ordinary shares and share options.

Zurit Levine, SVP of Business Development at CompuGen Ltd., executed trades involving ordinary shares and stock options under a Rule 10b5-1 plan.

Zurit Levine, SVP of Business Development at CompuGen Ltd., reports transactions involving ordinary shares and stock options under a Rule 10b5-1 trading plan.

Compugen Ltd. reports that its President and CEO, Ophir Eran, executed a Rule 10b5-1 trading plan, involving the acquisition of 5,625 ordinary shares and the disposition of 5,625 ordinary shares.

Compugen's SVP of Business Development, Zurit Levine, exercised options and subsequently sold 11,875 ordinary shares under a pre-arranged trading plan.